Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

Bevacizumab

Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months

DRUG

Cyclophosphamide

Once a day for 6 months

DRUG

Methotrexate

Twice daily for the first two days of every week for 6 months

DRUG

Capecitabine

"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"

Trial Locations (5)

27701

University of North Carolina, Durham

46202

Indiana University Cancer Center, Indianapolis

94122

University of California, San Francisco, San Francisco

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Indiana University School of Medicine

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

University of North Carolina

OTHER

lead

Harold J. Burstein, MD, PhD

OTHER

NCT00121134 - Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer | Biotech Hunter | Biotech Hunter